Immunology in the clinic review series; focus on cancer: Tumour-associated macrophages: Undisputed stars of the inflammatory tumour microenvironment

Research output: Contribution to journalArticle

Abstract

Mononuclear phagocytes are cells of the innate immunity that defend the host against harmful pathogens and heal tissues after injury. Contrary to expectations, in malignancies, tumour-associated macrophages (TAM) promote disease progression by supporting cancer cell survival, proliferation and invasion. TAM and related myeloid cells [Tie2 + monocytes and myeloid-derived suppressor cells (MDSC)] also promote tumour angiogenesis and suppress adaptive immune responses. These divergent biological activities are mediated by macrophages/myeloid cells with distinct functional polarization, which are ultimately dictated by microenvironmental cues. Clinical and experimental evidence has shown that cancer tissues with high infiltration of TAM are associated with poor patient prognosis and resistance to therapies. Targeting of macrophages in tumours is considered a promising therapeutic strategy: depletion of TAM or their 're-education' as anti-tumour effectors is under clinical investigation and will hopefully contribute to the success of conventional anti-cancer treatments.

Original languageEnglish
Pages (from-to)195-205
Number of pages11
JournalClinical and Experimental Immunology
Volume167
Issue number2
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Tumor Microenvironment
Allergy and Immunology
Macrophages
Neoplasms
Myeloid Cells
Adaptive Immunity
Phagocytes
Innate Immunity
Cues
Disease Progression
Monocytes
Cell Survival
Therapeutics
Cell Proliferation
Education

Keywords

  • Angiogenesis
  • Cancer
  • Inflammation
  • Myeloid cells
  • Tumour-associated macrophages

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

@article{4dc1567f800b4077a7c5aa6542204bf4,
title = "Immunology in the clinic review series; focus on cancer: Tumour-associated macrophages: Undisputed stars of the inflammatory tumour microenvironment",
abstract = "Mononuclear phagocytes are cells of the innate immunity that defend the host against harmful pathogens and heal tissues after injury. Contrary to expectations, in malignancies, tumour-associated macrophages (TAM) promote disease progression by supporting cancer cell survival, proliferation and invasion. TAM and related myeloid cells [Tie2 + monocytes and myeloid-derived suppressor cells (MDSC)] also promote tumour angiogenesis and suppress adaptive immune responses. These divergent biological activities are mediated by macrophages/myeloid cells with distinct functional polarization, which are ultimately dictated by microenvironmental cues. Clinical and experimental evidence has shown that cancer tissues with high infiltration of TAM are associated with poor patient prognosis and resistance to therapies. Targeting of macrophages in tumours is considered a promising therapeutic strategy: depletion of TAM or their 're-education' as anti-tumour effectors is under clinical investigation and will hopefully contribute to the success of conventional anti-cancer treatments.",
keywords = "Angiogenesis, Cancer, Inflammation, Myeloid cells, Tumour-associated macrophages",
author = "P. Allavena and A. Mantovani",
year = "2012",
month = "2",
doi = "10.1111/j.1365-2249.2011.04515.x",
language = "English",
volume = "167",
pages = "195--205",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Immunology in the clinic review series; focus on cancer

T2 - Tumour-associated macrophages: Undisputed stars of the inflammatory tumour microenvironment

AU - Allavena, P.

AU - Mantovani, A.

PY - 2012/2

Y1 - 2012/2

N2 - Mononuclear phagocytes are cells of the innate immunity that defend the host against harmful pathogens and heal tissues after injury. Contrary to expectations, in malignancies, tumour-associated macrophages (TAM) promote disease progression by supporting cancer cell survival, proliferation and invasion. TAM and related myeloid cells [Tie2 + monocytes and myeloid-derived suppressor cells (MDSC)] also promote tumour angiogenesis and suppress adaptive immune responses. These divergent biological activities are mediated by macrophages/myeloid cells with distinct functional polarization, which are ultimately dictated by microenvironmental cues. Clinical and experimental evidence has shown that cancer tissues with high infiltration of TAM are associated with poor patient prognosis and resistance to therapies. Targeting of macrophages in tumours is considered a promising therapeutic strategy: depletion of TAM or their 're-education' as anti-tumour effectors is under clinical investigation and will hopefully contribute to the success of conventional anti-cancer treatments.

AB - Mononuclear phagocytes are cells of the innate immunity that defend the host against harmful pathogens and heal tissues after injury. Contrary to expectations, in malignancies, tumour-associated macrophages (TAM) promote disease progression by supporting cancer cell survival, proliferation and invasion. TAM and related myeloid cells [Tie2 + monocytes and myeloid-derived suppressor cells (MDSC)] also promote tumour angiogenesis and suppress adaptive immune responses. These divergent biological activities are mediated by macrophages/myeloid cells with distinct functional polarization, which are ultimately dictated by microenvironmental cues. Clinical and experimental evidence has shown that cancer tissues with high infiltration of TAM are associated with poor patient prognosis and resistance to therapies. Targeting of macrophages in tumours is considered a promising therapeutic strategy: depletion of TAM or their 're-education' as anti-tumour effectors is under clinical investigation and will hopefully contribute to the success of conventional anti-cancer treatments.

KW - Angiogenesis

KW - Cancer

KW - Inflammation

KW - Myeloid cells

KW - Tumour-associated macrophages

UR - http://www.scopus.com/inward/record.url?scp=84855817522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855817522&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2249.2011.04515.x

DO - 10.1111/j.1365-2249.2011.04515.x

M3 - Article

C2 - 22235995

AN - SCOPUS:84855817522

VL - 167

SP - 195

EP - 205

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 2

ER -